Table 2.
Clinical trials for CAR-NK cell immunotherapy.
| NO. NCT | Other Name/ID Numbers | States | Start Date | Phase | Disease | Target | Sponsor locations | NK source |
|---|---|---|---|---|---|---|---|---|
| NCT00995137 | NKCD19 R01CA113482 NCI-2011-01226 |
Completed in May 2013. | October 2009 | I | B-Lineage Acute Lymphoblastic Leukemia | CD19 | St. Jude Children’s Research Hospital | PB-NK |
| NCT01974479 | NKCARCD19 | Suspended for an interim review of (CAR) CD19 research strategy | September 2013 | I | B-Lineage Acute Lymphoblastic Leukemia | CD20 | National University Health System, Singapore | PB-NK |
| NCT03056339 | 2016-0641 NCI-2018-01221 |
Active, not recruiting Primary results published.(119) | June 21, 2017 | I and II | B Lymphoid Malignancies | CD19 | M.D. Anderson Cancer Center | UCB-NK |
| NCT03383978 | EudraCT 2016-000225-39 | Recruiting | December 1, 2017 | I | Glioblastoma | HER2 | Johann Wolfgang Goethe University Hospital | NK-92 |
| NCT03415100 | NRC-NK-01 | Completed Results submitted in February 2021 | January 2, 2018 | I | Metastatic Solid Tumors | NKG2D | The Third Affiliated Hospital of Guangzhou Medical University | PB-NK |
| NCT03656705 | CNK-101 | Enrolling by invitation | September 29, 2018 | I | Non-small Cell Lung Carcinoma | PD-1 | Xinxiang medical university | NK-92 |
| NCT03692663 | TABP EIC-01 | Recruiting | December, 2018 | Early I | Castration-resistant Prostate Cancer | PSMA | Allife Medical Science and Technology Co., Ltd. | Unknown |
| NCT03824964 | CD19/CD22 CAR NK-BJZL-01 | Unknown | February 1, 2019 | Early I | Relapsed or Refractory B Cell Lymphoma | CD19/CD22 | Allife Medical Science and Technology Co., Ltd. | Unknown |
| NCT03692767 | CD22 CAR NK-BJZL-01 | Unknown | March 2019 | Early I | Relapsed and Refractory B Cell Lymphoma | CD22 | Allife Medical Science and Technology Co., Ltd. | Unknown |
| NCT03690310 | CD19 CAR NK-BJZL-01 | Unknown | March 2019 | Early I | Relapsed and Refractory B Cell Lymphoma | CD19 | Allife Medical Science and Technology Co., Ltd. | Unknown |
| NCT03692637 | Mesothelin Car NK-HNRM-01 | Unknown | March 2019 | Early I | Epithelial Ovarian Cancer | Mesothelin | Allife Medical Science and Technology Co., Ltd. | PB-NK |
| NCT04245722 | FT596-101 | Recruiting | March 19, 2020 | I | B-Cell Lymphoma, Chronic Lymphocytic Leukemia | CD19 | Fate Therapeutics | iPSC-NK |
| NCT04623944 | NKX101-101 | Recruiting | September 21, 2020 | I | Adults With AML or MDS | NKG2D | Nkarta Inc. | PB-NK |
| NCT05215015 | IBR733-T01 WX-IBR-7 |
Recruiting | November 30, 2020 | Early I | Acute Myeloid Leukemia | CD33/CLL1 | Wuxi People’s Hospital | Unknown |
| NCT04639739 | CAR NK for NHL | Not yet recruiting | December 17, 2020 | Early I | Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | CD19 | Xinqiao Hospital of Chongqing | Unknown |
| NCT04747093 | ITNK-2021 | Recruiting | January 29, 2021 | I and II | B Cell Malignancies | CD19 | Nanfang Hospital of Southern Medical University | Induced-T Cell Like NK cells |
| NCT04796675 | CAR-NK-CD19 cells | Recruiting | April 10, 2021 | I | B Lymphoid Malignancies | CD19 | Wuhan Union Hospital, China | CB |
| NCT04887012 | IR2021002168 | Recruiting | May 1, 2021 | I | Refractory or Relapsed B-cell Non Hodgkin Lymphoma | CD19 | Second Affiliated Hospital, School of Medicine, Zhejiang University | PB-NK |
| NCT05020678 | NKX019-101 | Recruiting | August 20, 2021 | I | Adults With B-cell Cancers | CD19 | Nkarta Inc. | PB-NK |
| NCT05137275 | IBR854-03 | Recruiting | November 24, 2021 | Early I | Locally Advanced or Metastatic Solid Tumors | 5T4 | Shanghai East Hospital | Unknown |
| NCT05008536 | BCMA NK for MM | Recruiting | October 1, 2021 | Early I | Relapsed or Refractory Multiple Myeloma | BCMA | Xinqiao Hospital of Chongqing | UCB-NK and CB-NK |
| NCT05247957 | CARNK-001 | Recruiting | October 13, 2021 | I | Relapsed or Refractory Acute Myeloid Leukemia | NKG2D | Hangzhou Cheetah Cell Therapeutics Co., Ltd | UCB-NK |
| NCT05213195 | CARNK-002 | Recruiting | December 10, 2021 | I | Refractory Metastatic Colorectal Cancer | NKG2D | Zhejiang University | Unknown |
| NCT04847466 | 10000096, 000096-C |
Recruiting | December 14, 2021 | II | Recurrent or Metastatic Gastric or Head and Neck Cancer | PD-L1 | National Cancer Institute (NCI) | NK-92 |
| NCT05008575 | CD33 CAR NK-AML | Recruiting | December 23, 2021 | I | Relapsed or Refractory Acute Myeloid Leukemia | CD33 | Xinqiao Hospital of Chongqing | Unknown |
| NCT05194709 | IBR854-T01, WX-IBR-8 |
Recruiting | December 30, 2021 | Early I | Advanced Solid Tumors | 5T4 | Wuxi People’s Hospital | Unknown |
| NCT05379647 | NK-002 (QN-019a) | Recruiting | November 4, 2021 | I | B-Cell Malignancies | CD19 | Zhejiang University | iPSC-NK |
| NCT05182073 | FT576-101 | Recruiting | November 24, 2021 | I | Multiple Myeloma | BCMA | Fate Therapeutics | iPSC-NK |
| NCT05110742 | 2021-0526 | Not yet recruiting | June 30, 2022 | I and II | Relapse or Refractory Hematological Malignances | CD5 | M.D. Anderson Cancer Center | CB-NK |
| NCT05092451 | 2021-0386 | Not yet recruiting | August 1, 2022 | I and II | Relapse or Refractory Hematological Malignances | CD70 | M.D. Anderson Cancer Center | CB-NK |
| NCT05336409 | CNTY-101-111-01 | Not yet recruiting | December 2022 | I | Relapsed or Refractory CD19-Positive B-Cell Malignancies | CD19 | Century Therapeutics, Inc. | iPSC-NK |
Allife Medical Science and Technology has just revised the completion date of NCT03692663. As for their other clinical trials, NCT03824964, NCT03692767, NCT03690310 and NCT03692637, we are looking forward to their renewal.